M
Michael F. McDermott
Researcher at University of Leeds
Publications - 153
Citations - 16117
Michael F. McDermott is an academic researcher from University of Leeds. The author has contributed to research in topics: Familial Mediterranean fever & Tumor necrosis factor alpha. The author has an hindex of 55, co-authored 148 publications receiving 14562 citations. Previous affiliations of Michael F. McDermott include Royal London Hospital & National Institute for Health Research.
Papers
More filters
Journal ArticleDOI
Genetic variants within the MAP kinase signalling network and anti-TNF treatment response in rheumatoid arthritis patients
Lydia R. Coulthard,John C. Taylor,Steve Eyre,James I. Robinson,Anthony G. Wilson,John D. Isaacs,Kimme L. Hyrich,Paul Emery,Anne Barton,Jennifer H. Barrett,Ann W. Morgan,Michael F. McDermott +11 more
TL;DR: More SNPs than would be expected by chance, mapping to the p38 signalling network, showed association with the anti-TNF response as a whole, and particularly with the response to infliximab and adalimumab.
Journal ArticleDOI
ER Stress: A Therapeutic Target in Rheumatoid Arthritis?
TL;DR: Current knowledge of the contribution of ER stress to the overall pathogenesis of RA is integrated, and some therapeutic implications of these discoveries are suggested.
Journal ArticleDOI
ENaC-mediated sodium influx exacerbates NLRP3-dependent inflammation in cystic fibrosis.
T. Scambler,Heledd H. Jarosz-Griffiths,Heledd H. Jarosz-Griffiths,Samuel Lara-Reyna,Shelly Pathak,C. Wong,C. Wong,J. Holbrook,J. Holbrook,Fabio Martinon,Fabio Martinon,Sinisa Savic,Sinisa Savic,Sinisa Savic,Daniel Peckham,Daniel Peckham,Michael F. McDermott,Michael F. McDermott +17 more
TL;DR: An enhanced proinflammatory signature is identified, as evidenced by increased levels of IL-18, IL-1β, caspase-1 activity and ASC-speck release in monocytes, epithelia and serum with CF-associated mutations; these differences were reversed by pretreatment with NLRP3 inflammasome inhibitors and notably, inhibition of amiloride-sensitive sodium (Na+) channels.
Journal ArticleDOI
Rilonacept in the treatment of chronic inflammatory disorders.
TL;DR: The desirable longer half-life of rilonacept offers potential alternatives to patients who do not tolerate daily injections very well or have difficulty with drug compliance, and suggests that it would also be a suitable treatment for CNICA/NOMID.
Journal ArticleDOI
Anakinra as a diagnostic challenge and treatment option for systemic autoinflammatory disorders of undefined etiology
Stephanie R Harrison,Dennis McGonagle,Sharmin Nizam,Stephen J. Jarrett,Jeroen Van der Hilst,Michael F. McDermott,Sinisa Savic +6 more
TL;DR: A retrospective case series demonstrates that the spectrum of poorly defined autoinflammatory disorders that show responsiveness to anakinra is considerable and seems a viable treatment option for patients, who are unresponsive to standard steroid/DMARD treatments.